Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTU-MultiHIV DNA Vaccine Safety and Immunogenicity in Healthy Volunteers
NCT02075983Phase 1Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GTU-MultiHIV B clade vaccine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Imperial College London. Primary endpoints: Immunogenicity and Safety. Status: unknown.
02
Drugs
GTU-MultiHIV B clade vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02075983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075983.